Communiqués Collegium Pharmaceutical, Inc.

Actions

COLL

US19459J1043

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
33,14 ^USD	+2,19 %		-3,24 %	+7,67 %

13/05	Collegium Pharmaceutical lance un programme de rachat d'actions accéléré de 35 millions de dollars	MT
10/05	COLLEGIUM PHARMACEUTICAL, INC. : Needham & Co. passe à neutre sur le dossier	ZM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Collegium to Participate in Jefferies Global Healthcare Conference	29/05	GL
Collegium Announces $35 Million Accelerated Share Repurchase Program	13/05	GL
Sweetgreen, Natera rise; Collegium Pharmaceutical, Akamai fall, 5/10/2024	10/05	AQ
Collegium Pharmaceutical: Q1 Earnings Snapshot	09/05	AQ
Collegium Reports First Quarter 2024 Financial Results	09/05	GL
Collegium Announces CEO Transition	09/05	GL
PTAB's Authority To Issue A Final Written Decision After A Statutory Deadline	03/05	AQ
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER	29/04	GL
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024	25/04	GL
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026	11/04	GL
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026	11/04	AQ
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference	03/04	GL
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference	03/04	AQ
Collegium Pharmaceutical: Q4 Earnings Snapshot	22/02	AQ
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results	22/02	GL
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results	22/02	AQ
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024	08/02	GL
Deadline Dexterity: PTAB Has Authority To Issue Decisions After Statutory Deadline	18/01	AQ
Collegium Provides 2024 Financial Guidance	03/01	GL
No Consequence For Board Issuing Final Written Decision Over 37 Months After Institution	13/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Collegium Pharmaceutical, Inc.

Actions

COLL

US19459J1043

Communiqués

Filtres